Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

Jim Williams, PhD, chief operating officer.

About T-cell Vaccination

For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in multiple sclerosis patients resulted in the in vivo induction of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-arm, 52-week, parallel-group study, whereby patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate.

All patients who complete the trial will be eligible to participate in an optional o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire-iReach/ -- Gateway Analytical ... the 9 th Annual Global Pharma Manufacturing ... September 8-9 th . The Global Pharma Manufacturing ... in small molecule and biologic pharmaceutical manufacturing. The ... that today,s manufacturers face, such as the increasing ...
(Date:8/28/2014)... , Aug. 28, 2014 /PRNewswire/ ... market research report is available in ... Therapeutics in Asia-Pacific Markets to 2020 ... Unmet Need in Newly Diagnosed and ... http://www.reportlinker.com/p02343492/Glioblastoma-Multiforme-Therapeutics-in-Asia-Pacific-Markets-to-2020---Novel-Therapeutic-Approaches-Target-High-Unmet-Need-in-Newly-Diagnosed-and-Recurrent-GBM.html Glioblastoma ...
(Date:8/28/2014)... MEETING, Pa. , Aug. 28, 2014 /PRNewswire-USNewswire/ ... community, patients, and media, both for the promise ... patient safety. The quick deployment of surgical robots ... technology are prompting facilities to evaluate their robotic ... the entire surgical team.    ECRI ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 2Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 3Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 4Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 5Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 6Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 7Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 8Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM 9Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5
... ANAHEIM, Calif., Feb. 7, 2011 UBM TechInsights ... the smartphone juggernaut will impact revenues, design strategies, and ... same way it has for many consumer products including ... "The question for traditional medical device companies is ...
... Feb. 7, 2011 Today the U.S. Food and Drug ... conduct postmarket surveillance studies to determine the length of time ... or other reasons. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... the temporal bone in the skull. A person may have ...
Cached Medicine Technology:UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases 2UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases 3UBM TechInsights Issues Warning to Medical Devices Industry About Possible Obsolescence as Reliance on Smartphones Increases 4FDA Orders Postmarket Surveillance of Certain TMJ Implants 2FDA Orders Postmarket Surveillance of Certain TMJ Implants 3
(Date:8/28/2014)... August 29, 2014 The Global and ... on the current state of the Oscilloscope industry in ... overview of the industry, including definitions, applications and industry ... analysis are provided with a focus on history, developments, ... between the international and Chinese situation is also offered. ...
(Date:8/28/2014)... information about the chance of ,overdiagnosis, through the NHS ... involved, according to research published in the British ... a survey of around 2,200 women, Cancer Research UK ... per cent felt they fully understood the information given ... up cancers that would never have gone on to ...
(Date:8/28/2014)... Arizona State University graduate student Anthony Gonzales, co-founder ... one of five finalists in Entrepreneur magazine’s 2014 College ... fourth consecutive year that an ASU student has been ... SafeSIPP, and JJ Tang, co-founder of Vantage Realized, were ... dominated the competition: Three of the five finalists were ...
(Date:8/28/2014)... exit strategy from the war, now may be the time ... to veterans, says a Perspective piece in the New ... doing more of the same is to fail to recognize ... structure pose in the longer run," said William Weeks, from ... David Auerbach, from the RAND Corporation, in the August issue ...
(Date:8/28/2014)... 2014 Allegheny Health Network ... regional partnership designed to advance sports nutrition education, ... young athletes, scholastic athletes and their families across ... & Mind Initiative will offer a comprehensive and ... and mental dynamics involved in pursuing athletic excellence,” ...
Breaking Medicine News(10 mins):Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 2Health News:Global Oscilloscope Industry (North America, Europe, Asia, and ROW) Forecast Report 2020 Now Available at ReportsnReports.com 3Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 2Health News:Arizona State University Grad Student in the Running for College Entrepreneur of the Year 3Health News:A VA exit strategy 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 2Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 3Health News:Allegheny Health Network and Come Ready Nutrition Announce Regional Partnership 4
... in an attempt to find out how various eating ... the blood pressures of meat eaters, fish eaters, vegetarians, ... Health Nutrition, showed how healthy eating habits could help ... in the comparative study - some with high blood ...
... on birth control pills have been linking them to ... pills. However, a new study published by Walter Spitzer, ... contradicted previous studies by stating that women who take ... no increased risk for heart attack compared to women ...
... observed a pill-sized camera and a CT scan may prove ... small intestine. The newly approved camera capsule, also known as ... before available. A patient swallows the pill and, for eight ... on the person's abdomen.// The pictures can then be viewed ...
... have discovered that it might be possible for tear-free GM ... the chemical in onions that makes you cry is not ... of Tokyo and Kyoto University,//tested the theory that the crying ... Alliinase plays a part in the chemical reactions that give ...
... that cloned animals tend to harbor genetic defects that ... the rational that reproductive cloning of humans should be ... be used safely for therapeutic cloning techniques, such as ... Parkinson's to diabetes. Cloned animals have major ...
... shown in a new study, that soy can lower cholesterol ... studies give more reason to dish up the soy protein ... fatty acids, which are found in abundance in fish, //flax ... health benefits. But researchers suggest they also produce physiological effects ...
Cached Medicine News:Health News:Cut meat to cut blood pressure 2Health News:No heart attack risk for women taking birth control pills 2Health News:Genetic failure in cloned animals 2Health News:Soy, Omega 3s convalesce artery health 2Health News:Soy, Omega 3s convalesce artery health 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: